Cytokinetics Announces Clinical And Preclinical Data Regarding Ispinesib For Breast C

[News]

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters, one summarizing interim Phase I clinical trial data evaluating ispinesib in the treatment of breast cancer and another containing preclinical data for ispinesib, were presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS) held on December 10-14, 2008.

More... (http://www.medicalnewstoday.com/articles/132906.php)